Apim Therapeutics

APIM Therapeutics Closes a Seed-Follow-Up Financing Round

Older News

TRONDHEIM, Norway, November 10, 2011 - Financing will be used to further advance preclinical development of APIM Therapeutics' anti-cancer lead compound, ATX-101, in selected tumor indications including blood cancer and solid tumors.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy